| abstract |
The present invention is an HDM2-p53 interaction inhibitor (S) -5- (5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridine-3-) for use in the treatment of hematological malignancies. Il) -6- (4-chloro-phenyl) -2- (2,4-dimethoxy-pyrimidine-5-yl) -1-isopropyl-5,6-dihydro-1H-pyrrolo [3,4-d] imidazole HDM2-p53 interaction inhibitor (S) -4-one (HDM201), administered according to an extended low-dose regimen characterized by a higher dose during induction and a lower dose during consolidation (S) -5. (5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl) -6- (4-chloro-phenyl) -2- (2,4-dimethoxy-pyrimidine-5-yl) ) -1-Isopropyl-5,6-dihydro-1H-pyrrolo [3,4-d] imidazol-4-one (HDM201). |